
QFINITY · News · Insights & Events
Shaping the regulated quality of tomorrow.
Articles and analysis from our own work across GxP, pharma, quality management, GAMP and AI - what is changing in the regulated environment, what it means in practice, and what is happening inside our company.
Latest articles




Global QMS concept for an international pharmaceutical company: design and implementation
Grown through acquisitions, an international pharmaceutical company needed a harmonized global QMS. QFINITY designed and implemented it along GAMP 5 and ITIL – across infrastructure, software development, and computerized system validation – including a training concept and a worldwide rollout.
This case study focuses on the design and implementation of a global QMS concept for an international pharmaceutical company.
Problem Statement
The client is an international company in pharmaceutical active ingredient research. Its services range from researching and developing new pharmaceutical compounds to building software platforms for specialized methods in this domain.
After years of significant growth through acquisitions, the company needed to consolidate its various quality management approaches into a harmonized global Quality Management System (QMS).
To achieve this objective, the client required:
Project Execution
In the initial phase, QFINITY analyzed the organization’s existing quality management systems and evaluated them against regulatory requirements and industry standards.
QFINITY then developed a new QMS concept covering the following areas:
As part of the implementation, QFINITY developed all necessary policies, directives, SOPs, work instructions, and document templates. It also created training materials for all relevant areas and planned and ran training sessions for the respective employee groups and departments.
Results and Benefits
The project was completed successfully on time and within the planned budget. Appropriately scaling the analysis, development, and rollout activities – and coordinating them efficiently – made this possible. Potential bottlenecks were identified early and avoided, keeping the overall project timeline on track.
The implemented global QMS significantly improved both efficiency and compliance. Globally harmonized processes and approaches ensured consistent compliance with regulatory requirements across the entire organization. Process efficiency increased substantially, and the company established a unified global understanding of quality.
The company’s internal quality assurance function reviewed the QMS approach and related documentation, and any inconsistencies identified were resolved promptly before rollout.
For more information about QFINITY’s case studies, check out our Project News.
ISPE EU Annual Conference | April 20-22, 2026
Meet QFINITY on site at the ISPE EU Annual Conference 2026 in Copenhagen and learn how to bring digital compliance, AI, and GxP requirements together in a safe, future-proof, and practical way.
QFINITY’s Contribution to ISPE Europe 2026
The digital transformation of the pharmaceutical industry is progressing rapidly. Artificial intelligence, cloud technologies, and data-driven automation are now integral to GxP-critical processes. At the same time, regulatory requirements for data integrity, transparency, and patient safety remain uncompromising.
Oliver Herrmann, CEO of QFINITY, is a member of the event’s Program Team. He also serves as Track Lead for the Digital Compliance track, together with Josef Trapl and Niels de Blende. In this role, he is responsible for the track’s structure, technical depth, and overall content direction.
Content Focus: Digital Compliance
The Digital Compliance track addresses one central question:
How do you ensure lasting GxP compliance in AI-enabled, cloud-based, and continuously evolving system landscapes?
1. GxP Principles in the Age of AI
2. From Document-Based to Data-Driven Validation
3. Data Integrity, Trust, and Decision-Making
4. Next Generation Digital Compliance
For more information about the event and to register for the ISPE EU Annual Conference, please visit the ISPE website.
ACDM26 Conference with QFINITY | March 15-17, 2026
QFINITY will participate in the ACDM26 Conference in Berlin. The international conference is one of the leading events for professionals in Clinical Data Management and clinical research. It also draws experts in regulatory affairs and digital innovation across the life sciences industry.
As part of the conference program, Frank Henrichmann, Senior Executive Consultant at QFINITY, will deliver a presentation titled “Rewriting the Rulebook: How AI Will Transform Computer System Validation.”
The presentation will explore how Artificial Intelligence (AI) could fundamentally transform Computerized System Validation (CSV) in GxP-regulated environments. Traditional validation approaches are often time-consuming, highly manual, and resource-intensive.
The session will demonstrate how modern AI technologies may one day analyze and structure requirements, generate and execute test cases, and automatically document validation evidence. This has the potential to make the validation of clinical systems more efficient. It could also enable continuous compliance monitoring and improve audit readiness.
At the same time, the presentation highlights that the success of this transformation depends heavily on high-quality, well-structured requirements. It will also address key challenges such as the regulatory acceptance of AI-generated evidence, the validation of the AI tools themselves, and the role of human oversight in AI-supported validation processes.
Key Learning Objectives of the Presentation
Participants will gain insights into three central aspects of AI-supported validation:
1. Application of AI in system validation
Understanding how AI technologies can be applied to the validation of GCP and other clinical systems. In particular, it shows how they can improve efficiency, test coverage, and compliance.
2. Importance of high-quality requirements
Recognizing the critical role that precise, structured, and complete requirements play in enabling successful AI-supported validation.
3. Transition to AI-supported validation processes
Identifying key challenges and practical steps involved in moving from traditional CSV approaches to AI-supported validation workflows in regulated environments.
Exchange at ACDM26
The ACDM26 conference provides a platform for international exchange on current developments in Clinical Data Management. It also covers emerging technological and regulatory challenges in clinical research.
QFINITY looks forward to contributing to the discussion. The focus will be on how AI, regulatory requirements, and technological innovation will shape the future of Computer System Validation.
You can find further information about the ACDM26 Conference here.